LUCID CAPITAL MARKETS Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $59

Benzinga Newsdesk www.benzinga.com Neutral 64.5%

Neg 0% Neu 64.5% Pos 0%

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $59.